CHICAGO — Effectively, that’s a wrap. The largest assembly in most cancers analysis — and, actually, one of many greatest annual conferences for the pharmaceutical business as an entire — has drawn to a detailed. What did we be taught from this yr’s annual assembly of the American Society of Scientific Oncology?
Right here’s one lesson: New most cancers medicines, given sufficient time, will be proven to have an effect on the factor sufferers care about most — whether or not they stay or die. The largest instance got here with outcomes of Tagrisso in non-small cell lung most cancers that’s nonetheless early sufficient to be surgically eliminated. In sufferers with a specific genetic mutation, the drug lower the demise fee in half. And that was the results of a decade-and-a-half of labor by researchers on the drug’s maker. STAT had the story of Susan Galbraith, AstraZeneca’s head of most cancers analysis, and her position in making that occur.
A few decade in the past researchers began to get enthusiastic about one other new expertise: CAR-T, through which a affected person’s white blood cells are engineered to assault tumors. Earlier this yr, one of many first kids cured with this tech, Emily Whitehead, spoke at a STAT occasion. Now she’s 18. At ASCO, we acquired statistical proof that sufferers with B-cell lymphoma who acquired Yescarta, a CAR-T made by Gilead, lived longer.